AHA Scientific Sessions 2026 Abstract · Nov 2, 2026

Modeling Optimal Timing for Initial and Repeat Coronary Artery Calcium Scoring in Individuals with Elevated Lipoprotein(a): The Multi-Ethnic Study of Atherosclerosis

By Khedagi A, Razavi AC, Blumenthal RS et al.

Background: Prior studies have identified the utility of coronary artery calcium (CAC) scoring among individuals with elevated lipoprotein(a) [Lp(a)]. However, the timing of initial and repeat CAC scoring in individuals with elevated Lp(a) remains unclear. Research Questions: To determine the optimal age of initial and repeat CAC scoring (among those with initial CAC of 0) among individuals with Lp(a) >50 mg/dL (approximately 125 nmol/L). Methods: Participants in the Multi-Ethnic Study of Atherosclerosis (MESA) study who had a baseline Lp(a) were included within this analysis. Participants underwent CAC testing at different follow-up visits 2, 3, 4, and 5 within the MESA study. Multivariable logistic regression models were used to estimate the modeled age associated with predicted probabilities of CAC >0 (at 15%, 20%, and 25% testing yield; number needed to screen [NNS] 6, 5, and 4 respectively) by sex and Lp(a) level, which included modeled ages beyond the MESA participant age range. Participants were then further stratified by risk factor burden. Survival models using a Weibull distribution were used to estimate the time to incident CAC and calculate time intervals for repeat testing based on testing yields of 15%, 20% and 25% (NNS of 6, 5, and 4, respectively) among individuals with initial CAC=0. A sensitivity analysis was performed using an Lp(a) threshold of 70 mg/dL. Results: A total of 6,700 MESA participants were included, of whom 3,362 had baseline CAC=0. The modeled estimated time to CAC >0 was lower in men compared to women across all Lp(a) levels and risk factors. Men with elevated Lp(a) [Lp(a) >50 mg/dL], compared to those without elevated Lp(a), had earlier estimated ages to initiate CAC testing only among those with diabetes. Men with elevated Lp(a) in the diabetes + additional risk factor group had the earliest recommended modeled testing ages (25% yield: 33.4 years; 20%: 29.7 years; 15%: 26.9 years, Figure 1A). Among women, those with elevated Lp(a) had earlier modeled initial CAC testing ages than women without elevated Lp(a) across all risk factor groups. The earliest recommended modeled ages to initiate CAC testing were among women with elevated Lp(a) and high-risk factor burden (25% yield: 46.7 years; 20%: 44.2 years; 15%: 42.3 years, Figure 1B). Among participants with CAC=0 at baseline, the estimated time to incident CAC >0 was consistently shorter in participants with elevated Lp(a) compared with those without elevated Lp(a) (4.2-5.8 vs 4.5-6.2 years, Figure 2). In a sensitivity analysis, time to develop incident CAC >0 in those with Lp(a) >70 mg/dL was similar to those with Lp(a) >50 mg/dL. Conclusion: Elevated Lp(a) was associated with earlier optimal age for CAC testing in men with diabetes and in women regardless of risk factor burden. Progression to incident CAC was similar, though modestly earlier in individuals with elevated Lp(a).

doi.org/10.1161/circ.154.suppl_1.5172Biomarkers

AgingResearch.News